featured
Efficacy and Safety of Canagliflozin in Patients With T2DM and Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Canagliflozin Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Diabetes Obes Metab 2014 Oct 01;16(10)1016-1027, JF Yale, G Bakris, B Cariou, J Nieto, E David-Neto, D Yue, E Wajs, K Figueroa, J Jiang, G Law, K Usiskin, G MeiningerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.